Paradox Immunotherapeutics Analysis: $10M Raised
What is Paradox Immunotherapeutics?
Monoclonal antibody treatment for protein misfolding diseases
Location
Toronto, Canada
Employees
1-10
Founded
2019
Product Features & Capabilities
- LX-96
- KX-99
- NX-86
Use Cases
Target misfolded proteins in ALS and Alzheimer's; Develop therapies for AL, ATTR, and ALECT2 amyloidosis; Conduct FDA clinical trials for lead candidates; Provide hope for patients with rare diseases; Combat multi-organ failure caused by protein misfolding
Other Considerations
Three pre-clinical stage antibodies with commercial interest; Team includes experts in monoclonal development and protein biochemistry; Addresses a global healthcare crisis affecting 300 people per million worldwide
See something that needs updating? Suggest edits to this profile.